KushCo Holdings, Inc. (OTCQB: KSHB) reported this morning that the company has been able to generate a total $51 million dollars in revenue for the year of 2018, with $19 million produced over the course of Q4.
KushCo Holdings is the umbrella company that owns companies such as Kush Bottles, Kush Energy, The Hybrid Creative, and Koleto Packaging Solutions. The company has increased their sales by 171% over the past year.
KushCo Holding’s has focused its business model on offering compliant packaging solutions to manufacturers involved in the cannabinoid product industry. Look for KushCo Holdings to grow even more rapidly as more states allow the medicinal and recreational consumption of cannabis products.
By avoiding being directly involved with the cultivation, manufacturing, or distribution of cannabinoid-based products, KushCo Holdings has built a public company with very little legal risk. They are effectively selling the proverbial “picks and shovels” of the green rush.
Their variety of different subsidiaries sells everything from compliant packaging materials, empty vape cartridges, cannabis pop bottles, to concentrate packaging not their websites. These products are sold to companies located in North America, South America, and Europe.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…